Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Lymphoid 1Dermatologic 1Breast 1

Conditions

Glioblastoma 18Carcinoma, Non-Small-Cell Lung 6Glioma 5Brain Neoplasms 5Head and Neck Neoplasms 4Neoplasms 3Neoplasm Metastasis 3Melanoma 3Esophageal Neoplasms 3Carcinoma, Squamous Cell 3Breast Neoplasms 3Astrocytoma 3Stomach Neoplasms 2Sarcoma 2Prostatic Neoplasms 2Pain 2Lung Neoplasms 2Gliosarcoma 2Central Nervous System Neoplasms 2Bone Neoplasms 2Uterine Neoplasms 1Urinary Bladder Neoplasms 1Stomatitis 1Small Cell Lung Carcinoma 1Sarcoma, Synovial 1Ovarian Neoplasms 1Oligodendroglioma 1Neuroectodermal Tumors 1Nervous System Diseases 1Neoplasms by Site 1

Interventions

hypericin 4zanolimumab 3mogamulizumab 3cobomarsen 3Vorinostat 3Bexarotene 3denileukin diftitox 2Vitamin B 12 2Panobinostat 2Folic Acid 2Amines 2A-dmDT390-bisFv(UCHT1) protein 210-propargyl-10-deazaaminopterin 2talimogene laherparepvec 1resminostat 1ontuxizumab 1navitoclax 1forodesine 1TTI-621 1Radiation 1N-(4-(1-benzoylpiperidin-4-yl)butyl)-3-(pyridin-3-yl)acrylamide 1Methotrexate 1Mechlorethamine 1MAC-ST-001 1Interleukin-12 Subunit p35 1Fentanyl 1Fenretinide 1Duration of Therapy 1Drug Therapy 1Brentuximab Vedotin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Mycosis Fungoides × Radiation × Clear all
NCT02890368 2023-04-05

Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides

Pfizer

Phase 1 Terminated
56 enrolled
BreastDermatologicLymphoidSarcoma

Breast Neoplasms, Carcinoma, Squamous Cell, Melanoma, Mycosis Fungoides, Sarcoma, Carcinoma, Merkel Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡